JLE

Bulletin du Cancer

MENU

Cardiac tolerability of paclitaxel-anthracyclin associations in breast cancer management Volume 90, issue 3, Mars 2003

Authors
Département d’oncologie médicale. Laboratoire d’oncopharmacologie, Centre Antoine-Lacassagne, 33, avenue de Valombrose, 06189 Nice Cedex 2. Département de radiothérapie, Institut Jules-Bordet, 121 boulevard de Waterloo, 1000 Bruxelles, Belgique.

Within the past decades there has been major interest in associating the paclitaxel into the management of breast cancer patients with a strong improvement of clinical results. Moreover, doxorubicin is historically one of the major chemotherapeutic agents in breast cancer treatment. So, investigations of the combination of the paclitaxel with doxorubicin have logically taken place in the strategy of breast cancer management. Also, this association became a standard of care neoadjuvantly in locally advanced breast cancer. The aim of this review of literature consists to make a special focus on cardiac toxicity occurring after doxorubicin and paclitaxel association and to give adequate directions for the next future in this promising combination.